WO2005007099A3 - Inhibiteurs de la pkb utilises comme agents antitumoraux - Google Patents

Inhibiteurs de la pkb utilises comme agents antitumoraux Download PDF

Info

Publication number
WO2005007099A3
WO2005007099A3 PCT/US2004/021834 US2004021834W WO2005007099A3 WO 2005007099 A3 WO2005007099 A3 WO 2005007099A3 US 2004021834 W US2004021834 W US 2004021834W WO 2005007099 A3 WO2005007099 A3 WO 2005007099A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor agents
pkb inhibitors
inhibition
pkb
inhibitors
Prior art date
Application number
PCT/US2004/021834
Other languages
English (en)
Other versions
WO2005007099A2 (fr
Inventor
Joel Kawakami
Matthew Duncton
Dan Sherman
Hai-Ying He
Alexander Kiselyov
Bronek Pytowski
Original Assignee
Imclone Systems Inc
Joel Kawakami
Matthew Duncton
Dan Sherman
Hai-Ying He
Alexander Kiselyov
Bronek Pytowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Joel Kawakami, Matthew Duncton, Dan Sherman, Hai-Ying He, Alexander Kiselyov, Bronek Pytowski filed Critical Imclone Systems Inc
Publication of WO2005007099A2 publication Critical patent/WO2005007099A2/fr
Publication of WO2005007099A3 publication Critical patent/WO2005007099A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés biaryle comprenant deux noyaux à six chaînons fondus, un noyau à six chaînons au moins étant substitué par un noyau thiophényle ou furanyle. Lesdits composés sont utilisés dans l'inhibition de la kinase PKB, le traitement du cancer, ou l'inhibition de la croissance tumorale.
PCT/US2004/021834 2003-07-10 2004-07-09 Inhibiteurs de la pkb utilises comme agents antitumoraux WO2005007099A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48633903P 2003-07-10 2003-07-10
US60/486,339 2003-07-10

Publications (2)

Publication Number Publication Date
WO2005007099A2 WO2005007099A2 (fr) 2005-01-27
WO2005007099A3 true WO2005007099A3 (fr) 2005-04-14

Family

ID=34079220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/021834 WO2005007099A2 (fr) 2003-07-10 2004-07-09 Inhibiteurs de la pkb utilises comme agents antitumoraux

Country Status (1)

Country Link
WO (1) WO2005007099A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1784175A4 (fr) 2004-08-23 2009-07-22 Merck & Co Inc Inhibiteurs de l'activite de akt
CN101115479A (zh) 2005-02-14 2008-01-30 默克公司 Akt活性抑制剂
EP1871376A4 (fr) 2005-04-12 2010-04-28 Merck Sharp & Dohme Inhibiteur de l'activite akt
PT1898903E (pt) 2005-06-10 2013-06-28 Merck Sharp & Dohme Inibidores da atividade de akt
EP1785423A1 (fr) * 2005-11-11 2007-05-16 Zentaris GmbH Pyridopyrazines et leur utilisation en tant que modulateurs de kinases
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
CA2628039A1 (fr) * 2005-11-11 2007-05-18 Aeterna Zentaris Gmbh Nouvelle pyridopyrazine et son utilisation pour la modulation de kinases
EP1790342A1 (fr) * 2005-11-11 2007-05-30 Zentaris GmbH Dérivés de pyridopyrazine et leur utilisation comme modulateurs de transduction de signal
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
MX2012002274A (es) 2009-09-03 2012-09-07 Bioenergenix Compuestos heterociclicos para la inhibicion de pask.
WO2011093365A1 (fr) * 2010-01-27 2011-08-04 協和発酵キリン株式会社 Composé hétérocyclique azoté
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8993758B2 (en) 2010-11-22 2015-03-31 Board Of Regents Of The University Of Nebraska Substituted quinoxalines and uses thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CA2823753C (fr) 2011-01-05 2019-03-12 Bioenergenix Llc Composes heterocycliques pour l'inhibition de la pask
JP6139415B2 (ja) * 2011-03-02 2017-05-31 バイオエナジェニックス Ｐａｓｋの阻害のための複素環化合物
US8916561B2 (en) 2011-03-02 2014-12-23 Bioenergenix, Llc Substituted quinoxaline compounds for the inhibition of PASK
EP2508184A1 (fr) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Dérivés de pyridopyrazine et leur utilisation
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014106763A1 (fr) * 2013-01-07 2014-07-10 Vichem Chemie Kutató Kft. Pyridopyrazines utilisés en tant qu'agents antinéoplasiques
AU2014214326B2 (en) 2013-02-07 2018-07-05 Prexton Therapeutics Sa Substituted quinoxaline derivatives and their use as positive allosteric modulators of mGluR4
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
AU2015238301B2 (en) 2014-03-26 2020-06-25 Astex Therapeutics Ltd Combinations
DK3122359T3 (da) 2014-03-26 2021-03-08 Astex Therapeutics Ltd Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CA2946130A1 (fr) * 2014-04-18 2015-10-22 Millennium Pharmaceuticals, Inc. Composes a base de quinoxaline et leurs utilisations
CN107438598A (zh) 2015-01-20 2017-12-05 米伦纽姆医药公司 喹唑啉和喹啉化合物及其用途
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
MX2018003564A (es) 2015-09-23 2018-06-18 Janssen Pharmaceutica Nv 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
AU2016328692B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv New compounds
CN105949079B (zh) * 2016-05-26 2017-09-29 河南大学 一种可见光催化制备n‑(2‑甲酰基苯基)n‑取代甲酰胺衍生物的方法
US11661411B2 (en) 2017-12-01 2023-05-30 Board Of Regents Of The University Of Nebraska Quinoxaline compounds and uses thereof
WO2021226135A1 (fr) 2020-05-04 2021-11-11 Amgen Inc. Composés hétérocycliques utilisés en tant que récepteur de déclenchement exprimé sur des agonistes de cellules myéloïdes 2 et procédés d'utilisation
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
CN113831347B (zh) * 2021-10-22 2022-10-04 广东海洋大学 一种6，7位二取代的2-（乙硫基）-蝶啶-4-胺衍生物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042463A1 (fr) * 1998-02-23 1999-08-26 Warner-Lambert Company Derives de quinoxaline substitues utilises comme antagonistes du recepteur de l'interleukine-8

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042463A1 (fr) * 1998-02-23 1999-08-26 Warner-Lambert Company Derives de quinoxaline substitues utilises comme antagonistes du recepteur de l'interleukine-8

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BENNET ET AL.: "Steric hindrance in reactions of substituted quinoxalines", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. PART2, 1928, pages 1960 - 1975, XP008043612 *
BERGSTROM ET AL.: "Cyclic ammono ketones and acid chlorides of the quinoxaline series", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 53, 1931, pages 1846 - 1853, XP002985503 *
BLANCHE ET AL.: "heterocyclizations in the pyrido[2,3-b]pyrazine series", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 31, no. 1, 1994, pages 161 - 166, XP002985505 *
FUSON ET AL.: "Acyloins from t-butylglyoxal", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 61, 1939, pages 1937 - 1940, XP002985504 *
MALKIN ET AL.: "Phenyl benzyl diketone and some derivatives", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 127, 1925, pages 369 - 377, XP008043611 *
STEVENS ET AL.: "Subsituted sulfaquinoxalines. I. The isolation and synthesis of 3-hydroxy-2-sulfanilamindoquinoxalines and of related quinoxalines", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 68, 1946, pages 1035 - 1039, XP002244383 *

Also Published As

Publication number Publication date
WO2005007099A2 (fr) 2005-01-27

Similar Documents

Publication Publication Date Title
WO2005007099A3 (fr) Inhibiteurs de la pkb utilises comme agents antitumoraux
WO2005037198A3 (fr) Preparation d'azabenzimidazoles 1,7-disubstitues comme inhibiteurs de kinases
EP1675552A4 (fr) Preparation d'azabenzimidazoles 1,6-disubstitues comme inhibiteurs de kinases
WO2006138511A3 (fr) Composes et procedes pour le traitement du cancer
TW200621230A (en) Anti-tumor compounds
ATE381557T1 (de) Rho-kinase inhibitoren
WO2003002595A3 (fr) Nouveaux inhibiteurs de dipeptidylpeptidase iv et leurs utilisations en tant qu'agents anti-cancereux
MY148617A (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
WO2005021544A3 (fr) Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
GB0121490D0 (en) Ciompounds
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
CY1112570T1 (el) Θεραπεια καρκινων με μετασταση
WO2003039545A3 (fr) Utilisation d'inhibiteurs de i$g(k)b kinase pour traiter le cancer
EP1667685A4 (fr) Inhibiteurs du canal potassique a base de quinazoline
WO2003090680A3 (fr) Nouveaux derives de phenyle inducteurs d'apoptose
WO2005021510A3 (fr) Heterocycles c-2 benzimidazole servant d'inhibiteurs de kinase
GB0121494D0 (en) Compounds
MX2008001838A (es) Sales y polimorfos de un inhibidor de vegf-r.
SE0203747D0 (sv) New use
AU2003236701A8 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
WO2003028652A3 (fr) Utilisation de benzopyranones pour le traitement ou la prevention d'un cancer primitif du cerveau ou d'une metastase cerebrale
DK1261325T3 (da) Tumorinhiberende sammensætninger, der indeholder nitroacridiner
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
WO2003004631A3 (fr) Utilisation d'inhibiteurs de l'expression ou de l'activite de p8/com1 pour le traitement des tumeurs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase